Compare SCNI & SXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCNI | SXTC |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | Israel | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 1.8M |
| IPO Year | 2014 | 2017 |
| Metric | SCNI | SXTC |
|---|---|---|
| Price | $0.26 | $2.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 289.9K | 110.0K |
| Earning Date | 05-11-2026 | 08-19-2019 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $0.03 |
| 52 Week High | $3.47 | $6.98 |
| Indicator | SCNI | SXTC |
|---|---|---|
| Relative Strength Index (RSI) | 33.39 | 61.62 |
| Support Level | N/A | $1.88 |
| Resistance Level | $1.05 | $2.74 |
| Average True Range (ATR) | 0.03 | 0.32 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 10.51 | 67.90 |
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.